Jump to:
navigation,
search
Cannabidiol
Systematic (
IUPAC) name2-[(1
R,6
R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diolClinical data
AHFS/
Drugs.comInternational Drug NamesPregnancy cat.?
Legal statusSchedule II (Can)
Unscheduled (USA)Identifiers
CAS number13956-29-1
Y
ATC codeNone
PubChemCID 644019DrugBanknoneChemSpider24593618
Y
UNII19GBJ60SN5
YChemical data
FormulaC21
H30
O2
Mol. mass314.46
SMILESeMolecules &
PubChem
- InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(114(2)3/h9,12-13,17-18,22-23H,2,5-8,10-11H2,1,3-4H3/t17-,18+/m0/s1
Y
Key:ZTGXAWYVTLUPDT-ZWKOTPCHSA-N
Y
Physical data
Melt. point66 °C (151 °F)
Boiling point180 °C (356 °F)
(Range: 160°C-180°C)
[1]
N
(what is this?) (verify)
Cannabidiol (
CBD) is a
cannabinoid found in
Cannabis. It is a major constituent of the plant, representing up to 40% in its extracts.
[2]
It has displayed
sedative effects in animal tests.
[3] Some research, however, indicates that CBD can increase alertness.
[4] It may decrease the rate of THC clearance from the body, perhaps by interfering with the
metabolism of THC in the
liver.
Medically, it has been shown to relieve
convulsion,
inflammation,
anxiety, and
nausea, as well as inhibit
cancer cell growth.
[5] Recent studies have shown cannabidiol to be as effective as
atypical antipsychotics in treating
schizophrenia.
[6] Studies have also shown that it may relieve symptoms of
dystonia.
[7][8]
In November 2007, it was reported that CBD reduces growth of aggressive human
breast cancer cells
in vitro and reduces their invasiveness.
A 2008 study published in the
British Journal of Psychiatry showed significant differences in
Oxford-Liverpool Inventory of Feelings and Experiences scores between three groups: The first consisted of non-cannabis users, the second consisted of users with
Δ9-THC detected, and the third consisted of users with both Δ9-THC and CBD detected. The Δ9-THC only group scored significantly higher for unusual experiences than the Δ9-THC and CBD group, whereas the Δ9-THC and CBD group had significantly lower
introvertive anhedonia scores than the Δ9-THC only group and non-cannabis user group. This research indicates that CBD acts as an anti-psychotic and may counteract the potential effects of THC on individuals with latent schizophrenia.
[9]